Comparison of a point-of-care platelet function testing to light transmission aggregometry in patients undergoing percutaneous coronary intervention pretreated with aspirin and clopidogrel

Point of Care

Volumn 10, Issue 1, 2011, Pages 35-39

  Polena, Sotir ^a   Zazzali, Kathleen M ^a   Shaikh, Hafeza ^a   Goyal, Rakesh ^a   Kossidas, Konstantinos ^a   Carville, David ^b   Soffer, Daniel ^a  

^a LENOX HILL HOSPITAL   (United States)

^b INDIANA UNIVERSITY SOUTH BEND   (United States)

Author keywords

light transmission aggregometry (LTA); PlateletWorks; Point of care (POC)

Indexed keywords

EID: 79952289474     PISSN: 1533029X     EISSN: 15330303     Source Type: Journal    
DOI: 10.1097/POC.0b013e31820f852e     Document Type: Article

References (27)

1. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol. 1963;168:178-195.
2. Born GVR, Hardisty RM. Platelets in Human Blood Coagulation, Haemostasis and Thrombosis. 2nd ed. London: R Biggs Blackwell Scientific Publications; 1976:168-201.
3. Storey RF, Wilcox RG, Hepinstall S. Differential effects of glycoprotein GPIIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency: implications for assay methodology and comparison of different antagonists. Circulation. 1998;198:1616-1621. (Pubitemid 28500383)
4. Carville DGM, Schlesker PA, Guyer KE, et al. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol. 1998;30:171-177. (Pubitemid 29152672)
5. Shaffer KE, Pearman DT, Galen RS, et al. A rapid platelet function assay used to regulate platelet transfusion prophylaxis following cardiopulmonary bypass surgery. J Extra Corpor Technol. 2004;36:145-148. (Pubitemid 38924740)
6. Lau WC, Walker CT, Ogilby D, et al. Evaluation of a bed-side platelet function assay: performance and clinical utility. Ann Card Anesth. 2002;5:33-42.
7. Carville DGM, Guyer E. Hemostasis testing: past, present, and future. IVD Technol. 2000;6:49-56.
8. Steinhubl SR, Berger PB, Mann JT 3rd, et al. CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420. (Pubitemid 35340537)
9. Podczasy JJ, Lee J, Vucenik I. Evaluation of whole-blood lumi-aggregation. Clin Appl Thromb Hemost. 1997;3:190-195.
10. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 System: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24:195-202. (Pubitemid 28180831)
11. Smith JW, Steinhubl SR, Lincoff AM. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999;99:620-625. (Pubitemid 29077360)
12. TEG. Available at: http://www.anes.saga-med.ac.jp/ispub/journals/IJA/ Vol1N3/teg.htm. Accessed February 2010.
13. AspirinWorks. Available at:http://stattechnologies.com/index.php? module=pagemaster&PAGE-user-op=view-page&PAGE- id=26&MMN-position= 50:50. Accessed February 2010.
14. Bates ER, Mukherjee D, Lau WC. Drug-drug interactions involving anti-platelet agents. Eur Heart J. 2003;24:1707-1709. (Pubitemid 37236858)
15. Jarvis B, Simpson K. Clopidogrel: a reviewof its use in the prevention of atherothrombosis. Drug. 2000;60:247-277.
16. Van Werkum JW, Kleibeuker M, Postma S, et al. A comparison between the PlateletWorks assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. Int J Cardiol. 2008;6:51.
17. Breddin HK. Can platelet aggregometry be standardized? Platelet. 2005;16:151-158. (Pubitemid 40910903)
18. Eikelboom J, Hirsch J, Weitz JI, et al. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-1655. (Pubitemid 34298607)
19. Eidelman RS, Herbert PR, Weisman SM, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163:2006-2010. (Pubitemid 37151241)
20. Harrington RA, Hodgson PK, Larsen RL. Antiplatelet therapy. Circulation. 2003;108:e45-e47.
21. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardio. 2005;46:1705-1709. (Pubitemid 41531626)
22. Cattaneo M. Aspirin and clopidogrelVefficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980-1987. (Pubitemid 39482419)
23. Gum P, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-235. (Pubitemid 32721947)
24. Muller I, Bestas F, Schultz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003; 89:783-787. (Pubitemid 36603418)
25. Guyer KE, Carville DGM, Lau WC. Platelet protection using the glycoprotein IIb/IIIa inhibitor tirofiban in a patient with heparin induced thrombocytopenia undergoing aortic valve replacement requiring cardiopulmonary bypass. Point of Care J Near Patient Test Technol. 2003;2:119-124.
26. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-Care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-assessing Ultegra) multicenter study. Circulation. 2001;103:2572.
27. Kelly RV, Steinhubl S. Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention. Heart. 2005;91:iii16-iii19. (Pubitemid 40769247)